Pharmacogenetics and population pharmacokinetics: Impact of the design on three tests using the SAEM algorithm

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 4, 2009, Pages 317-339

  Bertrand, Julie ^a   Comets, Emmanuelle ^a   Laffont, Céline M ^b   Chenel, Marylore ^c   Mentré, France ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Design; Nonlinear mixed effects models; Pharmacogenetics; Pharmacokinetics; SAEM; Single nucleotid polymorphism; Test

Indexed keywords

DNA;

ALGORITHM; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; COMPUTER PROGRAM; DNA SEQUENCE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG METABOLISM; GENOTYPE; HUMAN; NONLINEAR MIXED EFFECTS MODEL; NONLINEAR SYSTEM; PHARMACOGENETICS; PRIORITY JOURNAL; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; STOCHASTIC MODEL;

ALGORITHMS; ANALYSIS OF VARIANCE; BAYES THEOREM; BIOTRANSFORMATION; COMPUTER SIMULATION; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESEARCH DESIGN;

EID: 69049105269     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9124-x     Document Type: Article

References (45)

1. EMEA (2008) ICH topic E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. Technical report, EMEA
2. FDA (2008) E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. Technical report, FDA
3. EMEA (2007) Reflection paper on the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products. Technical report, EMEA
4. XP Hu JM Xu YM Hu Q Mei XH Xu 2007 Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in chinese people J Clin Pharmacol Ther 32 517 524
5. Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, COPHAR2-ANRS Study Group (2008) Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. Br J Clin Pharmacol 65:548-57
6. Y Yamasaki I Ieiri H Kusuhara T Sasaki M Kimura H Tabuchi Y Ando S Irie JA Ware Y Nakai S Higuchi Y Sugiyama 2008 Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (Bcrp) gene polymorphisms in humans Clin Pharmacol Ther 84 95 103
7. D Li W Lu JY Zhu J Gao YQ Lou GL Zhang 2007 Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients Clin Pharm Ther 32 505 515
8. J Bertrand E Comets F Mentré 2008 Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters J Biopharm Stat 18 1084 1102
9. Sheiner L, Beal S (1998) NONMEM Version 5.1. University of California, NONMEM Project Group, San Francisco
10. Lavielle M (2008) MONOLIX (MOdèles NOn LInéairesà effets miXtes). MONOLIX Group, Orsay, France, 2008. http://www.software.monolix. org/index.php
11. Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon D (2009) Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen-ANRS 111 trial. Fundam Clin Pharmacol. in press
12. Bertrand J, Treluyer JM, Panhard X, Tran A, Rey SE, Salmon-Céron D, Duval X, Mentré F, COPHAR2-ANRS 111 Study Group (2009) Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol 65:667-678
13. Retout S, Comets E, Le Nagard H, Bazzoli C, Mentré F (2007) PFIM Interface 2.1. UMR738, INSERM, Université Paris 7, Paris, France, http://www.pfim.biotstat.fr
14. S Retout E Comets A Samson F Mentré 2007 Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates Stat Med 26 5162 5179
15. GC Pillai Mentré F JL Steimer 2005 Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science J Pharmacokinet Pharmacodyn 32 161 183
16. B Deylon M Lavielle E Moulines 1999 Convergence of a stochastic approximation version of EM algorithm Ann Stat 27 94 128
17. A Samson M Lavielle F Mentré 2007 The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model Stat Med 26 4860 4875
18. GEP Box SL Andersen 1955 Permutation theory in the derivation of robust criteria and the study of departures from assumption J R Stat Soc Ser B Meth 17 1 34
19. SL Beal 2001 Ways to fit a PK model with some data below the quantification limit J Pharmacokinet Pharmacodyn 28 481 504
20. J Fellay C Marzolini E Meaden D Back T Buclin J Chave 2002 Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter gene MDR1: a pharmacogenetic study Lancet 359 30 36
21. C Solas N Simon NP Drogoul S Quaranta V Frixon-Marin V Bourgarel-Rey C Brunet JA Gastaut A Durand B Lacarelle I Poizot-Martin 2007 Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients Br J Clin Pharmacol 64 353 362
22. T Sakaeda T Nakamura K Okumura 2002 MDR1 genotype-related pharmacokinetics and pharmacodynamics Biol Pharm Bull 25 1391 1400
23. C Marzolini E Paus T Buclin RB Kim 2003 Polymorphisms in human MDR1 (p-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 13 33
24. Sackett DL, Haynes RB, Guyatt GH, Tugwellrada P (1991) Clinical epidemiology. A basic science for clinical medecine, 2nd edn. Little Brown, Boston.
25. MO Karlsson RM Savic 2007 Diagnosing model diagnostics Clin Pharm Ther 82 17 20
26. Robert CP (1994) The Bayesian Choice. A decision-theoretic motivation. Springer-Verlag, New York
27. Verbeke G, Molenberghs G (2000) Linear mixed models for longitudinal data. Springer-Verlag, New York
28. X Panhard A Samson 2009 Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects Biostatistics 10 121 135
29. U Wählby EN Jonsson MO Karlsson 2001 Assessment of actual significance levels for covariate effects in NONMEM J Pharmacokinet Pharmacodyn 28 231 252
30. JV Gobburu J Lawrence 2002 Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences Pharm Res 19 92 98
31. PL Bonate 2005 Covariate detection in population pharmacokinetics using partially linear mixed effects models Pharm Res 22 541 549
32. E Comets F Mentré 2001 Evaluation of tests based on individual versus population modeling to compare dissolution curves J Biopharm Stat 11 107 123
33. X Panhard F Mentré 2005 Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials Stat Med 24 1509 1524
34. GEP Box 1954 Some theorems on quadratic forms applied in the study of analysis of variance problems, i. effect of inequality of variance in the one-way classification Ann Math Stat 25 290 302
35. JF Crow 1999 Hardy, Weinberg and language impediments Genetics 152 821 825
36. X Panhard AM Taburet C Piketti F Mentré 2007 Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients Stat Med 26 1268 1284
37. C Dartois A Lemenuel-Diot C Laveille B Tranchand M Tod P Girard 2007 Evaluation of uncertainty parameters estimated by different population pk software and methods J Pharmacokinet Pharmacodyn 34 289 311
38. E Kuhn M Lavielle 2005 Maximum likelihood estimation in nonlinear mixed effects models Comput Stat Data Anal 49 1020 38
39. DB White CA Walawander DY Liu TH Grasela 1992 Evaluation of hypothesis testing for comparing two populations using NONMEM analysis J Pharmacokinet Biopharm 20 295 313
40. PI Lee 2001 Design and power of a population pharmacokinetic study Pharm Res 18 75 82
41. Manly BFJ (1998) Randomization, bootstrap and Monte Carlo methods in biology, 2nd edition. Chapman & Hall, London
42. DA Elston 1998 Estimation of denominator degrees of freedom of F-distributions for assessing Wald statistics for fixed-effect factors in unbalanced mixed models Biometrics 54 1085 1096
43. Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, Becquemont L, Ouk V, Mentré F, Taburet AM (2009) Inter- and intra-patient variabilities in nevirapine plasma concentrations in HIV-infected cambodian patients and the effect of CYP2B6 genetic polymorphism: ANRS 12154 study. 16th conference on retroviruses and opportunistic infections, Montreal, Canada
44. SB Gabriel SF Schaffner H Nguyen JM Moore J Roy B Blumenstiel J Higgins M DeFelice A Lochner M Faggart SN Liu-Cordero C Rotimi A Adeyemo R Cooper R Ward ES Lander MJ Daly D Altshuler 2002 The structure of haplotype blocks in the human genome Science 296 2225 2229
45. L Zhang SL Beal LB Sheiner 2003 Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance J Pharmacokinet Pharmacodyn 30 387 404